WO2006014973A2 - Pharmaceutical dosage forms including rasagiline - Google Patents
Pharmaceutical dosage forms including rasagiline Download PDFInfo
- Publication number
- WO2006014973A2 WO2006014973A2 PCT/US2005/026517 US2005026517W WO2006014973A2 WO 2006014973 A2 WO2006014973 A2 WO 2006014973A2 US 2005026517 W US2005026517 W US 2005026517W WO 2006014973 A2 WO2006014973 A2 WO 2006014973A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- pharmaceutical dosage
- rasagiline
- disease
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- R-PAI R(+) -N-propargyl-1-aminoindan
- Rasagiline has been reported to be a selective inhibitor of the B-form of the enzyme monoamine oxidase (“MAO-B") and is useful in treating Parkinson's disease and various other conditions by inhibition of MAO-B in the brain.
- MAO monoamine oxidase
- Parkinson's disease Epidemiology, pathophysiology, and guidelines for management, " CNS-Drugs, 1999, 11(6) : 435-
- Delayed gastric emptying can be a cause of increased inhibition of peripheral MAO, and can contribute to the cheese effect.
- MAO inhibitors that selectively inhibit MAO-B are largely devoid of the potential to cause cheese effect.
- the present inventions provides an oral pharmaceutical dosage form comprising rasagiline and adapted to retard or inhibit the release of rasagiline in the stomach.
- Figure 1 Sectional perspective, side and top down view of a solid dosage form with a recessed core tablet of active ingredient in a compressed annular body of powder or granular material in accordance with the invention.
- the present invention provides an oral pharmaceutical dosage form comprising rasagiline and adapted to retard or inhibit the release of rasagiline in the stomach.
- the oral pharmaceutical dosage form is a tablet, a capsule, or a core sheathed in an annular body.
- the pharmaceutical dosage form is a tablet.
- the pharmaceutical dosage form comprises an enteric coating.
- the pharmaceutical dosage form is a core sheathed in an annular body.
- the core is a tablet.
- the annular body is an annular sheath.
- the core has an enteric coating.
- the pharmaceutical dosage form is a capsule.
- the capsule comprises solid inactive particles.
- the particles are spheres, microparticles, nanoparticles or pellets made by spheronization, or a mixture thereof.
- the particles are spheres. In a further embodiment, the particles are comprised ol sugars, alcohols, polyols or celluloses, or mixtures thereof .
- the particles are comprised of sugars .
- the solid inactive particles comprise rasagiline.
- the particles are coated with rasagiline.
- the particles comprise an enteric coating.
- the enteric coating comprises polymeric methacrylate.
- the polymeric methacrylate is methacrylic acid - ethyl acrylate copolymer (1:1) dispersion 30 percent.
- the enteric coating further comprises a plasticizer.
- the plasticizer is triethyl citrate.
- the oral pharmaceutical dosage form upon administration to a patient, releases rasagiline substantially in the intestinal tract.
- the rasagiline is released substantially in the small intestine.
- the pharmaceutical dosage form has a rasagiline release profile in a United States
- the pharmaceutical dosage form has a rasagiline release profile in a United States Pharmacopoeia Apparatus II of less than 5% dissolution in 500 ml 0. IN HCl at 37 0 C and 50 rpm after 3 hours, and more than 95% dissolution in phosphate buffer at a pH of 6.8 after an additional 2 hours.
- the pharmaceutical dosage form has a rasagiline release profile in a United States Pharmacopoeia Apparatus II of less than 3% dissolution in 500 ml 0.1N HCl at 37°C and 50 rpm after 3 hours, and more than 97% dissolution in phosphate buffer at a pH of 6.8 after an additional 2 hours.
- the pharmaceutical dosage form has a rasagiline release profile in a United States Pharmacopoeia Apparatus II of less than 2% dissolution in 500 ml 0.1N HCl at 37 0 C and 50 rpm after 3 hours, and more than 98% dissolution in phosphate buffer at a pH of 6.8 after an additional 2 hours .
- the pharmaceutical dosage form has a rasagiline release profile in a United States Pharmacopoeia Apparatus II of less than 1% dissolution in 500 ml 0.1N HCl at 37 0 C and 50 rpm after 3 hours, and more than 99% dissolution in phosphate buffer at a pH of 6.8 after an additional 2 hours.
- the present invention provides a method of treating a patient suffering from Parkinson's disease, brain ischemia, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, nerve damage, dementia, Alzheimer's type dementia, senile dementia, depression, memory disorders, hyperactive syndrome, attention deficit disorder, multiple sclerosis, schizophrenia, or an affective illness, comprising administering to the patient the oral dosage form.
- the present invention provides a method for treating a patient suffering from Parkinson's disease.
- t the patient presents impaired gastric motility.
- the present invention provides the use of the pharmaceutical dosage form for the preparation of a medicament for the treatment of a patient suffering from Parkinson's disease, brain ischemia, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, nerve damage, dementia, Alzheimer's type dementia, senile dementia, depression, memory disorders, hyperactive syndrome, attention deficit disorder, multiple sclerosis, schizophrenia, or an affective illness.
- the present invention provides the use for the treatment of a patient suffering from Parkinson's disease.
- the patient presents impaired gastric motility.
- th,e present invention provides the pharmaceutical dosage form for use in treating a patient suffering from Parkinson's disease, brain ischemia, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, nerve damage, dementia, Alzheimer's type dementia, senile dementia, depression, memory disorders, hyperactive syndrome, attention deficit disorder, multiple sclerosis, schizophrenia, or an affective illness.
- the present invention provides the pharmaceutical dosage form for use in treating a patient suffering from Parkinson's disease.
- the patient presents impaired gastric motility.
- the instant invention provides a solution to the problem of peripheral MAO inhibition by providing pharmaceutical dosage forms comprising rasagiline which are adapted to inhibit the release or absorption of rasagiline in the stomach (i.e. delay the release of rasagiline until at least a portion of the dosage form has traversed the stomach) .
- This avoids or minimizes absorption of rasagiline in the stomach, thereby avoiding or minimizing the potential cheese effect.
- the pharmaceutical dosage form may be comprised of an acid resistant excipient which prevents the dosage form or parts thereof from contacting the acidic environment of the stomach.
- the acid resistant excipient may coat the rasagiline in the form of an enteric coated tablet, capsule, or gelatin capsule.
- Enteric coating in the context of this invention, is a coating which prevents the dissolution of an active ingredient in the stomach. This is determined by measuring the dissolution of the pharmaceutical dosage form in acidic solution, as defined by USP methods. Even in enteric pharmaceutical dosage forms, some of the dosage form may dissolve in the
- stomach • stomach; however, the dosage form may still be considered enteric according to USP standards.
- enteric coating is a polymeric methacrylate, most especially where the polymeric methacrylate is methacrylic acid-co-ethyl acrylate (1:1) .
- the enteric coating can contain a plasticizer, e.g. triethyl citrate.
- Enteric coatings are generally described in, e.g., United States Pharmacopeia, 26 th Rev. /National Formulary, 21 st Ed., 2002, ⁇ 724> Drug Release, Delayed- Release (Enteric-Coated) Articles - General Drug Release Standard, 2160-2161; Pharmaceutical Dosage Forms and Drug Delivery Systems, H.C. Ansel, L.V. Allen, Jr., N.G. Popovich (Lippincott Williams & Wilkins, pub., 1999), Modified-Release Dosage Forms and Drug Delivery Systems, 223, 231-240) .
- the present invention provides an oral pharmaceutical dosage form including rasagiline and that is a tablet provided with an enteric coating.
- the present invention also provides an oral pharmaceutical dosage form including rasagiline and that is a tablet that is formulated with an acid-resistant excipient other than a coating.
- the acid-resistant excipient can be a diluent or, preferably, a binder or disintegrant .
- Acid-resistant diluents and acid-resistant disintegrants are chosen, and pharmaceutical formulations containing them compressed into dosage forms, so that the dosage form (e.g. tablet) resists break-up in the stomach, thereby inhibiting or retarding release of the active pharmaceutical ingredient in the stomach.
- the dosage forms of this embodiment can have an enteric coating.
- Acid-resistant diluents and disintegrants do not swell or dissolve to a significant extent at pH less than about 6.
- the present invention also provides an oral pharmaceutical dosage form including rasagiline and that is a capsule having particles, such as spheres, microparticles, nanoparticles, or pellets of materials such as sugars, alcohols, polyols, or cellulosics, the particles having a coating of rasagiline and a further coating that is an enteric coating.
- Capsules containing enteric coated rasagiline pellets are useful to overcome the obstacles in treating patients with Parkinson's disease or related disorders who experience delayed gastric emptying.
- the small size of the enteric coated pellets can easily pass through the stomach and into the intestine. This limits the risk of prolonged exposure to acidic environment, which may cause standard enteric coated tablets to fail, thereby releasing rasagiline prematurely in the stomach.
- enteric coatings may be compromised by being exposed to acid for extended periods especially when being exposed to mechanical forces caused by the natural churning of the stomach.
- the enteric coat may start to leak or may fail altogether.
- the present invention also provides an oral pharmaceutical dosage form including rasagiline, useful for treating patients with Parkinsonism, fabricated such that a core tablet is coated with an enteric coating before it is sheathed in an annular body.
- the enteric coating serves to inhibit or retard drug release in the stomach and allow drug release to commence in the small intestine.
- the dosage form of this embodiment of the present invention can be made as described in published United States Patent Application 2004/0052843, hereby incorporated by reference in its entirety.
- the core tablet has first and second opposed surfaces and a circumferential surface.
- “Sheathing” means that the annular body encircles the core tablet and is in contact with the core tablet about its circumferential surface, but leaves opposed surfaces of the core tablet substantially exposed.
- the annular body can be formed of any powdered or granular pharmaceutically acceptable excipients and can itself include and active pharmaceutical ingredient.
- the annular body can include diluents, binders, disintegrants, glidants, lubricants, flavorants, colorants and the like. Powdering and granulation with conventional excipients and the techniques for forming compressed bodies therefrom with given characteristics in terms of friability, hardness and freedom from capping is well within the knowledge of those skilled in the art of tableting.
- Preferred excipients for forming the annular body include hydroxypropyl cellulose (e.g., KlucelTM) , hydroxypropyl methylcellulose (e.g., MethocelTM) , microcrystalline cellulose [e.g., AvicelTM) , starch, lactose, sugars, polyvinylpyrrolidone ⁇ e.g., KollidonTM, PlasdoneTM) , calcium phosphate, and MicrocelLaclOOTM (a 25:75 mixture of microcrystalline cellulose and lactose) .
- core tablet 1 containing rasagiline is recessed in the annular body 2.
- Core tablet 1 has opposed first and second surfaces 3 and 4 and an outer circumferential surface 5 extending between the opposed surfaces.
- Core tablet 1 is preferably cylindrical or disk shaped for ease of manufacture, but need not be so.
- the maximum distance across either of the opposed surfaces 3 or 4 is preferably from about 2 mm to about 12 mm, more preferably from about 4 mm to about 7 mm, most preferably about 5 mm.
- Opposed surfaces 3 and 4 can be flat, concave or convex and are preferably flat for bearing modest axial compression forces exerted by flat pressing surfaces during formation of the annular body about the core tablet.
- annular body 2 is preferably cylindrically shaped, but it can have any cross-section, such as oval, elliptical or oblong.
- the outer diameter is preferably of from about 5 mm to about 15 mm, more preferably of from about 7 mm to about 12 mm, most preferably about 9 mm.
- the inner diameter can be any size up to about 2 mm less than the outer diameter. A narrow- inner diameter less than 2 mm may slow release of rasagiline if an excipient in the annular body swells upon contact with gastric fluid. However, in some embodiments, a lower limit 0.5 mm may still be useful.
- the inner diameter is 3 mm or greater.
- Annular body 2 has opposed first and second annular faces 6 and 7, an outer circumferential surface 8 extending between the annular faces from their outer edges, and an inner circumferential surface 9 extending between the annular surfaces from their inner edges, thus defining an annulus .
- inner circumferential surface 9 of annular body 2 consists of three longitudinal (axial) segments.
- First and second segments 10 and 11 are terminal and do not contact the sides of the core tablet. They are separated by an internal third segment 12 that contacts the outer circumferential surface 5 of core tablet 1.
- Opposed surfaces 3 and 4 of the core tablet are therefore recessed from annular faces 6 and 7 of the annular body.
- Opposed surfaces 3 and 4 are preferably recessed from about 0.5 mm to about 4 mm, more preferably about 1.5 mm relative to the annular faces 6 and 7 of the annular body (said recessed distance corresponding to the length of the corresponding terminal segment) .
- the recess depth of surfaces 3 and 4 can be the same or it can be different.
- Recessing the core tablet does not significantly alter the release profile of the core tablet because a sizable portion of the surface of the core tablet is in fluid communication with the environment.
- one or both of opposed surfaces 3 and 4 can be flush with annular faces 6 and 7 of the annular body without deleterious effect when the core tablet is protected, such as by a coating.
- Voids 13 and 14 fill with gastric fluid when the dosage form is immersed in gastric fluid after reaching the stomach. Gastric fluid passes through the voids to contact the core tablet and the drug leaves through the voids after it is dissolved.
- Voids 13 and 14 are preferably from about 0.5 mm to about 10 mm, more preferably from about 3 mm to about 6 mm and most preferably about 4.5 mm in width (measured parallel to first or second opposed surfaces) .
- Opposed surfaces 3 and 4 of the core tablet are preferably substantially exposed, i.e., they are not substantially covered by the annular body.
- “Substantially exposed” means that less than about 50% of each of the opposed surfaces is concealed or hidden from visual inspection by the annular body. Such differences may result in inner segment 12 being offset from terminal segments 10 and 11, which, themselves, can have different longitudinal cross sections, e.g., have different diameters, as depicted in Fig. 1.
- the cross section of the annulu ⁇ defined by inner circumferential surface 9 can be uniform throughout its length.
- Both the core tablet and the annular body may be formed into any suitable shape, as the rate of release of rasagiline is determined by the formulation and shape of the core tablet, not by diffusion through the annular body. Specific shapes can be achieved by use of specifically designed punches.
- the core tablet and the annular body are cylindrical in shape.
- the exposed surfaces of the core tablet may be of any suitable shape.
- the exposed surfaces of the core tablet are circular or oval .
- the shape of one of the portions can be changed without adjusting the formulation.
- the powder or granular material may be pressed around the core tablet into a body having an oval cross-section rather than a circular cross-section to achieve a faster rate of release (resulting from increased surface area) .
- the core tablet may have a hole extending from one axial face to the other in order to increase the surface and thereby increase the release rate. The release rate can be further controlled through changes to the diameter of the hole.
- the present invention provides an oral pharmaceutical dosage form useful for treating a condition selected from the group consisting of: Parkinson's disease, brain ischemia, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, nerve damage, dementia, Alzheimer's type dementia, senile dementia, depression, memory disorders, hyperactive syndrome, attention deficit disorder, multiple sclerosis, schizophrenia, and affective illness, but with a reduced risk of peripheral MAO inhibition that is typically associated with administration of rasagiline with known oral dosage forms.
- a condition selected from the group consisting of: Parkinson's disease, brain ischemia, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, nerve damage, dementia, Alzheimer's type dementia, senile dementia, depression, memory disorders, hyperactive syndrome, attention deficit disorder, multiple sclerosis, schizophrenia, and affective illness, but with a reduced risk of peripheral MAO inhibition that is typically associated with administration of rasagiline with known oral dosage forms.
- Tablets may contain suitable binders, lubricants, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents.
- the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, gelatin, agar, starch, sucrose, glucose, methyl cellulose, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, microcrystalline cellulose and the like.
- Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn starch, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, povidone, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
- Lubricants used in these dosage forms include sodium oleate, sodium stearate, sodium benzoate, sodium acetate, sodium chloride, stearic acid, sodium stearyl fumarate, talc and the like.
- Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, croscarmellose sodium, sodium starch glycolate and the like.
- substantially release of rasagiline refers to a greater than 50%, 60%, 70%, 80% or 90% release of rasagiline.
- the tablet dissolution profile was analyzed using United States Pharmacopeia method ⁇ 724> for coated tablets. After 120 minutes in 0.IN HCl, the tablets were transferred to phosphate buffer solution.
- Example 2 Enteric coated rasagilin ⁇ inner core tablet sheathed in a placebo annular body
- enteric coated core tablet was prepared as described below.
- the enteric coated tablet was sheathed in an annular body as described in published United States Publication No. 2004/0052843, published March 18, 2004, incorporated herein above.
- Rasagiline granulate Rasagiline mesylate (40 grams) and a spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75:25) (Microcelac 100TM) (360 grams) were mixed in a Diosna P 1/6 high shear granulator at 380 rpm for 5 minutes. Purified water (130 grams) was added over the next minute while continuing to granulate at 380 rpm. The granulate was then massed for a further 1 minute at the same speed. The formed granulate was dried for 30 minutes in a Diosna Mini Lab fluidized bed drier to less than 1.5% volatiles at an inlet temperature of 60 0 C and a fan setpoint of 50%. The volatile content was tested at 105 0 C using a Sartorious MA 30 LOD tester.
- the dried granulate was milled using a Quadro Comill with a screen of 1143/x. Two sublots were produced so as to have enough material for the next stage.
- Tableting mixture The milled, dry, rasagiline granulate (558.0 grams) , was mixed in the dry state with Microcelac
- Tablet formation The dry mix powder was pressed into tablets on a Kilian RTS 20 tablet press using 5mm flat beveled punches. The tablets weighed an average of 75.0 mg, had a hardness of 8.7 Kp and a tablet thickness of 2.75 mm. The weight of the tablets produced was 2238.7 grams.
- Enteric coating Purified water (1044 grams) was placed in a mixing vessel. Talc (38.4 grams) , and triethylcitrate (38.4 grams) were added and the mixture was stirred for 15 minutes with a magnetic stirrer. Eudragit L-30 D55TM (1279.2 grams) was added and the mixture stirred gently. The coating mixture was passed through a 150 ⁇ screen and then continually mixed gently.
- Rasagiline core tablets (2238.7 grams) were placed in the drum of a Hi coater perforated pan coater and heated to 28-3O 0 C while the drum was turning at 7 rpm.
- the coating mixture was sprayed onto the tablets in the perforated pan coater turning at 12 rpm with the tablet bed maintained at 28 -30 0 C with the inlet air temperature set at 60 0 C until an average of 6.5 mg per tablet of enteric coat had been added to the tablets .
- the tablets were air dried in the drum for five minutes after the spraying was halted and subsequently dried on an aluminum tray in a drying oven set at 40 degrees for 24 hours.
- Tableting mixture Polyethylene oxide (Polyox WSR-N-750TM ,' 600 grams) , Microcelac 100TM(48 ⁇ grams) , ethylcellulose (Ethocel 7 cps, 600 grams) and polyvinylpyrollidone (Povidone K-30TM, 300 grams) were placed in a 5 liter V mixer and mixed for 5 minutes. Magnesium stearate NF/EP (14 grams) was added and the V mixer operated for a further half a minute. The yield of the dry mix of powders was 1990.1 grams.
- Tablet formation The enteric coated rasagiline inner cores were added to the tablet feeder and the tableting mixture was added to the powder feeder of a Manesty LP39 press using the special spring loaded core rod tooling for making the annular sheathed tablets .
- the lower punch was flat beveled of 9 mm diameter and an inner hole (for the core rod) of 5 mm diameter.
- the upper punch was flat beveled of 9 mm diameter with a protrusion that was 1.2 mm tall and 5 mm diameter with slight tapering.
- the final tablets so formed weighed an average of 310 mg, had a hardness of 6.4 Kp and a tablet thickness of 5.4mm.
- Each tablet contained the equivalent of 1 mg rasagiline as the mesylate salt in the enteric coated inner core.
- the tablets were tested for drug release in a United States Pharmacopeia Apparatus II in 500 ml 0. IN HCl at 37 0 C and 50 rpm for 3 hours and then in phosphate buffer at a pH of 6.8 for an additional 2 hours.
- the concentration of rasagiline was measured by HPLC analysis.
- the results are given in Table 3.
- the enteric coated tablets before their insertion into the annular sheath were also tested. These results are also given in Table 3.
- the rasagiline When transferred to a neutral buffer, the rasagiline was released in an immediate fashion.
- the annular sheath did not damage the enteric coating.
- the annular sheath When used in patients with gastric motility problems the annular sheath will be effective in protecting the enteric coating against mechanical forces in the gastrointestinal tract.
- Example 3 Rasagiline capsules containing enteric coated particles
- Particles for capsule filling were made using the ingredients listed in Table 4.
- PEG 6000 was mixed with water to form a solution. Rasagiline mesylate was then added and the solution was mixed. Hydroxypropyl methylcellulose was added to water, and the two solutions were combined and mixed. Suglets were placed in a Wurster fluid bed drier and the combined solution was sprayed on to the Suglets.
- the inlet temperature was 55 0 C
- the outlet temperature was between 29 0 C and 47°C.
- the spray rate was between 8 and 16 gram/min.
- the airflow rate was between 50-120 m 3 / hour.
- the percentage of coating was calculated as Eudragit weight/rasagiline coated particle weight.
- Triethyl citrate and water were homogenized, and Eudragit was added to attain a dispersion which contained 45.4% water.
- the drug coated pellets were placed in the Wurster fluid bed drier a second time.
- the dispersion was sprayed at a rate of between 8 and 16 g/min.
- the inlet temperature was between 33 0 C and 48 0 C, and the outlet temperature was between 25°C and 45 0 C.
- the airflow rate was between 40 and 120 m 3 / hour.
- the enteric coated pellets were dried for 90 minutes. Six batches of enteric coated pellets were formed with different amounts of coating in each batch.
- formulation F is effective in protecting the spheres from being dissolved in the stomach, thereby eliminating cheese effect in patients who are treated with the capsules.
- Capsules comprising spheres as in formulation F would be effective in treating Parkinson's patients because the spheres maintain integrity in stomach-like conditions for two hours, and are easily soluble in intestine-like conditions.
- Particles for capsule filling were made using the ingredients listed in Table 8.
- PEG 6000 was mixed with water to form a solution, and sodium lauryl sulfate was added. Rasagiline mesylate was added and the solution was mixed. Hydroxypropyl methylcellulose was added to water and the two solutions were combined and mixed. Suglets were placed in a Wurster fluid bed drier and the combined solution was sprayed on to the suglets.
- the inlet temperature was 55 0 C and the outlet temperature was between 29 0 C and 47 0 C.
- the spray rate was between 8 and 6 g/min.
- the airflow rate was between 50-120 mVhour.
- Triethyl citrate and water were homogenized, and Eudragit was added to attain a dispersion which contained 45.4% water.
- the drug coated pellets were placed in the Wurster fluid bed drier for a second time.
- the dispersion was sprayed at a rate of between 8 and 16 g/min.
- the inlet temperature was between 33°C and 48 0 C and the outlet temperature was between 25°C and 45 0 C.
- the airflow rate was between 40 and 120 ⁇ vVhour. After coating, the enteric coated pellets were dried for 90 minutes.
- the enteric coated pellets were then filled into Gelatin capsules, size 1.
- the dissolution profile based on USP procedures of the capsules is shown below in Table 9.
- the capsules were placed in in HCl 0.1 N. After 120 minutes in 0.1 N HCl, the dosage form was transferred to phosphate buffer solution.
- Rasagiline immediate release reference standard tablets were prepared using the ingredients listed in Table 10
- Rasagiline mesylate, mannitol, half of the colloidal silicon dioxide, starch and pregelatinized starch were mixed in a Diosna P-800 mixer for about 5 minutes. Water was added and the mixture was mixed further. The granulate was dried and the remainder of the colloidal silicon dioxide was added. The granulate was ground in a Frewitt mill and stearic acid and talc were added. The granulate was mixed for five minutes in a tumbler and was tableted.
- Delayed release capsules were prepared as in Example 4. Immediate release tablets were prepared as a reference standard as in Example 5.
- a single dose, crossover comparative PK study was performed in 12 healthy male volunteers in the fasting state. Each patient was administered a delayed release formulation in the form of 2 capsules as described in Example 4, and an immediate release formulation in the form of 2 tablets as described in Example 5. There was a separation of at least one week between the administrations of the two formulations.
- Plasma concentrations of rasagiline and of its active metabolite, 1-aminoindan were measured at the following times (in hours) : 0.00, 0.08, 0.17, 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.50, .4.00, 5.00, 6.00, 8.00, 12.00, and 24.00.
- C 1113x is the mean maximum measured plasma concentration.
- T 1 - J1x is the mean time at which the maximum concentration was measured.
- AUC 0 - t is the mean area under the concentration-time curve from time zero (predose) to the time of the last quantifiable concentration. This measurement was calculated using a linear trapezoidal method.
- Delayed release tablets were prepared as in Example 2. Immediate release tablets were prepared as a reference standard as in Example 5.
- a single dose, crossover comparative PK study was performed in 11 healthy male volunteers, in the fasting state. Each patient was administered a delayed release formulation in the form of 2 tablets as described in Example 2, and an immediate release formulation in the form of 2 tablets as in Example 5. There was a washout period of at least 21 days between the administrations of ⁇ the two formulations. Plasma concentrations of rasagiline and of its active metabolite, 1-aminoindan, were measured at the following times (in hours) : 0, 0.08, 0.17, 0.33, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48.
- C mx is the mean maximum measured plasma concentration.
- T n ⁇ x is the mean time at which the maximum concentration was measured.
- AUC 0 _ t is the mean area under the concentration-time curve from time zero (predose) to the time of the last quantifiable concentration. This measurement was calculated using a linear trapezoidal method.
- the C max for the delayed release dosage forms was lower than the C ma ⁇ in the immediate release tablets.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05782669A EP1778196A4 (en) | 2004-07-26 | 2005-07-26 | Pharmaceutical dosage forms including rasagiline |
AU2005269416A AU2005269416B2 (en) | 2004-07-26 | 2005-07-26 | Pharmaceutical dosage forms including rasagiline |
CA002574925A CA2574925A1 (en) | 2004-07-26 | 2005-07-26 | Pharmaceutical dosage forms including rasagiline |
JP2007523735A JP2008507586A (en) | 2004-07-26 | 2005-07-26 | Pharmaceutical administration containing rasagrine |
IL180706A IL180706A0 (en) | 2004-07-26 | 2007-01-15 | Pharmaceutical dosage forms including rasagiline |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59135904P | 2004-07-26 | 2004-07-26 | |
US60/591,359 | 2004-07-26 | ||
US60624104P | 2004-09-01 | 2004-09-01 | |
US60/606,241 | 2004-09-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006014973A2 true WO2006014973A2 (en) | 2006-02-09 |
WO2006014973A3 WO2006014973A3 (en) | 2006-04-13 |
Family
ID=35787777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/026517 WO2006014973A2 (en) | 2004-07-26 | 2005-07-26 | Pharmaceutical dosage forms including rasagiline |
Country Status (7)
Country | Link |
---|---|
US (1) | US20060018957A1 (en) |
EP (1) | EP1778196A4 (en) |
JP (1) | JP2008507586A (en) |
AU (1) | AU2005269416B2 (en) |
CA (1) | CA2574925A1 (en) |
IL (1) | IL180706A0 (en) |
WO (1) | WO2006014973A2 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1827409A2 (en) * | 2004-11-24 | 2007-09-05 | Teva Pharmaceutical Industries Ltd. | Rasagiline orally disintegrating compositions |
US7598420B1 (en) | 2005-12-06 | 2009-10-06 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
WO2010026993A1 (en) | 2008-09-03 | 2010-03-11 | 武田薬品工業株式会社 | Method for improving absorbability of preparation, and preparation having improved absorbability |
WO2010070090A1 (en) * | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Solid composition containing the ingredient rasagiline |
EP2218444A2 (en) | 2009-01-23 | 2010-08-18 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
WO2010111264A2 (en) * | 2009-03-24 | 2010-09-30 | Dr. Reddy's Laboratories Ltd. | Rasagiline formulations |
EP2246321A1 (en) | 2009-01-23 | 2010-11-03 | Teva Pharmaceutical Industries Ltd | Delayed release rasagiline formulation |
JP2011509295A (en) * | 2008-01-11 | 2011-03-24 | テバ ファーマシューティカル インダストリーズ リミティド | Rasagiline formulation, its preparation and use |
WO2011095973A1 (en) * | 2010-02-03 | 2011-08-11 | Pharma Two B Ltd. | Extended release formulations of rasagiline and uses thereof |
WO2010100219A3 (en) * | 2009-03-05 | 2011-08-11 | Sandoz Ag | Pharmaceutical composition containing rasagiline mesylate |
WO2011136376A1 (en) | 2010-04-30 | 2011-11-03 | 武田薬品工業株式会社 | Enteric tablet |
WO2011136373A1 (en) | 2010-04-30 | 2011-11-03 | 武田薬品工業株式会社 | Enteric tablet |
EP2600841A2 (en) * | 2010-05-30 | 2013-06-12 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of rasagiline |
WO2013105092A1 (en) * | 2012-01-12 | 2013-07-18 | Pharma Two B Ltd. | Fixed dose combination therapy of parkinson's disease |
EP2764862A1 (en) * | 2013-02-06 | 2014-08-13 | Galenicum Health S.L. | Immediate release tablets of rasagiline hemitartrate |
EP2796130A3 (en) * | 2013-02-06 | 2015-02-25 | Galenicum Health S.L. | Immediate release tablets of rasagiline hemitartrate |
EP2939669A1 (en) | 2009-12-22 | 2015-11-04 | Teva Pharmaceutical Industries, Ltd. | 3-keto-n-propargyl-1-aminoindan |
US9504657B2 (en) | 2012-01-12 | 2016-11-29 | Pharmatwob Ltd. | Fixed dose combination therapy of Parkinson's disease |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2526944B1 (en) | 2002-11-15 | 2016-06-01 | Teva Pharmaceutical Industries Limited | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
WO2006089164A1 (en) * | 2005-02-17 | 2006-08-24 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
US7815942B2 (en) * | 2005-02-23 | 2010-10-19 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
JP2009521402A (en) * | 2005-11-17 | 2009-06-04 | テバ ファーマシューティカル インダストリーズ リミティド | Method for the separation of propargylated aminoindan |
CA2643235C (en) | 2006-02-21 | 2014-06-17 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
CN101442997B (en) * | 2006-04-03 | 2012-11-14 | 泰华制药工业有限公司 | Use of rasagiline for the treatment of restless legs syndrome |
US7807715B2 (en) * | 2006-06-09 | 2010-10-05 | Ucb Pharma Gmbh | Pharmaceutical compositions comprising fesoterodine |
EP1892233A1 (en) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | New salts of the active component rasagiline |
MX2009006251A (en) * | 2006-12-14 | 2009-10-12 | Teva Pharma | Crystalline solid rasagiline base. |
PL2101570T3 (en) * | 2006-12-14 | 2013-07-31 | Teva Pharma | Tannate salt of rasagiline |
US20100303901A1 (en) * | 2007-04-26 | 2010-12-02 | Eyal Shimoni | Oral delivery of proteins and peptides |
EP1987816A1 (en) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate of a rasagiline salt with a water-soluble inactive ingredient |
US20090062400A1 (en) * | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
US20100008983A1 (en) * | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
EA201170018A1 (en) * | 2008-06-13 | 2011-08-30 | Тева Фармасьютикал Индастриз, Лтд. | Razagilin to change the flow of Parkinson's disease |
EP2299992A4 (en) | 2008-06-19 | 2015-10-21 | Teva Pharma | Process for preparing and drying solid rasagiline base |
EP2299993A4 (en) * | 2008-06-19 | 2014-08-20 | Teva Pharma | Process for purifying rasagiline base |
SI2451771T1 (en) | 2009-07-09 | 2014-10-30 | Ratiopharm Gmbh | Salts of rasagiline and pharmaceutical preparations thereof |
US9205577B2 (en) * | 2010-02-05 | 2015-12-08 | Allergan, Inc. | Porogen compositions, methods of making and uses |
US9138309B2 (en) | 2010-02-05 | 2015-09-22 | Allergan, Inc. | Porous materials, methods of making and uses |
US11202853B2 (en) * | 2010-05-11 | 2021-12-21 | Allergan, Inc. | Porogen compositions, methods of making and uses |
RU2587330C2 (en) | 2010-07-27 | 2016-06-20 | Тева Фармасьютикал Индастриз Лтд. | Use of rasagiline for treatment of olfactory dysfunction |
EP2598136A4 (en) | 2010-07-27 | 2015-03-25 | Teva Pharma | Dispersions of rasagiline citrate |
CN103188933A (en) * | 2010-10-26 | 2013-07-03 | 泰华制药工业有限公司 | Deuterium enriched rasagiline |
CA2851433A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | R(+)-n-methyl-propargyl-aminoindan |
EP2766002A4 (en) | 2011-10-10 | 2015-07-01 | Teva Pharma | R(+)-n-formyl-propargyl-aminoindan |
EP2884972A4 (en) | 2012-08-17 | 2016-05-11 | Teva Pharma | Parenteral formulation of rasagiline |
IN2013MU01782A (en) * | 2013-05-20 | 2015-06-26 | Cadila Healthcare Ltd |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003011255A1 (en) | 2001-07-04 | 2003-02-13 | Sun Pharmaceutical Industries Limited | Gastric retention controlled drug delivery system |
WO2003068186A1 (en) | 2002-02-11 | 2003-08-21 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
IL99759A (en) * | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
IL118836A (en) * | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
CA2275425C (en) * | 1996-12-18 | 2009-08-04 | Michael Chorev | Aminoindan derivatives |
AU2472499A (en) * | 1998-01-27 | 1999-08-09 | Thomas N. Thomas | Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl |
US20020137786A1 (en) * | 1998-02-12 | 2002-09-26 | William G. Tatton | Deprenyl compounds to treat viral infections and reduce tissue damage associated therewith |
US6139875A (en) * | 1998-09-29 | 2000-10-31 | Eastman Chemical Company | Aqueous enteric coating composition and low gastric permeability enteric coating |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6123968A (en) * | 1999-03-23 | 2000-09-26 | Mendez; Alejandro | Composition for extending shelf life for fresh fruits and vegetables without the use of refrigeration |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20040052843A1 (en) * | 2001-12-24 | 2004-03-18 | Lerner E. Itzhak | Controlled release dosage forms |
IL162459A0 (en) * | 2001-12-24 | 2005-11-20 | Teva Pharma | Dosage form with a core table of active ingredientsheathed in a compressed annular body of powder o r granular material, and process and toolin |
US20040010038A1 (en) * | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
JP2005525377A (en) * | 2002-03-04 | 2005-08-25 | サマセット ファーマシューティカルズ, インコーポレイテッド | Method for prevention and treatment of peripheral neuropathy by administration of desmethyl selegiline |
US20040166159A1 (en) * | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
AU2003288902A1 (en) * | 2002-09-06 | 2004-04-08 | Genteric, Inc. | Microcapsules and methods of use |
EP2526944B1 (en) * | 2002-11-15 | 2016-06-01 | Teva Pharmaceutical Industries Limited | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
US7735024B2 (en) * | 2003-10-29 | 2010-06-08 | Intel Corporation | Methods and apparatus to provide a handheld pointer-based user interface |
ZA200704917B (en) * | 2004-11-24 | 2008-11-26 | Teva Pharma | Rasagiline orally disintegrating compositions |
US7815942B2 (en) * | 2005-02-23 | 2010-10-19 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
JP2009521402A (en) * | 2005-11-17 | 2009-06-04 | テバ ファーマシューティカル インダストリーズ リミティド | Method for the separation of propargylated aminoindan |
US7572834B1 (en) * | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
CA2643235C (en) * | 2006-02-21 | 2014-06-17 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
CN101442997B (en) * | 2006-04-03 | 2012-11-14 | 泰华制药工业有限公司 | Use of rasagiline for the treatment of restless legs syndrome |
EP1892233A1 (en) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | New salts of the active component rasagiline |
MX2009006251A (en) * | 2006-12-14 | 2009-10-12 | Teva Pharma | Crystalline solid rasagiline base. |
PL2101570T3 (en) * | 2006-12-14 | 2013-07-31 | Teva Pharma | Tannate salt of rasagiline |
EP1987816A1 (en) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate of a rasagiline salt with a water-soluble inactive ingredient |
US20090062400A1 (en) * | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
CN101909438A (en) * | 2008-01-11 | 2010-12-08 | 泰华制药工业有限公司 | Rasagiline formulations, their preparation and use |
US20100008983A1 (en) * | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
EA201170018A1 (en) * | 2008-06-13 | 2011-08-30 | Тева Фармасьютикал Индастриз, Лтд. | Razagilin to change the flow of Parkinson's disease |
EP2299992A4 (en) * | 2008-06-19 | 2015-10-21 | Teva Pharma | Process for preparing and drying solid rasagiline base |
EP2299993A4 (en) * | 2008-06-19 | 2014-08-20 | Teva Pharma | Process for purifying rasagiline base |
US20100010098A1 (en) * | 2008-07-11 | 2010-01-14 | Walter Elffrink | Polymorphs of rasagiline hydrochloride |
US20100029987A1 (en) * | 2008-07-29 | 2010-02-04 | Dipharma Francis S.R.I. | Crystalline Form of Rasagiline and Process for the Preparation Thereof |
US20100189790A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
-
2005
- 2005-07-26 CA CA002574925A patent/CA2574925A1/en not_active Abandoned
- 2005-07-26 EP EP05782669A patent/EP1778196A4/en not_active Withdrawn
- 2005-07-26 US US11/190,623 patent/US20060018957A1/en not_active Abandoned
- 2005-07-26 JP JP2007523735A patent/JP2008507586A/en active Pending
- 2005-07-26 WO PCT/US2005/026517 patent/WO2006014973A2/en active Application Filing
- 2005-07-26 AU AU2005269416A patent/AU2005269416B2/en not_active Ceased
-
2007
- 2007-01-15 IL IL180706A patent/IL180706A0/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003011255A1 (en) | 2001-07-04 | 2003-02-13 | Sun Pharmaceutical Industries Limited | Gastric retention controlled drug delivery system |
WO2003068186A1 (en) | 2002-02-11 | 2003-08-21 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
Non-Patent Citations (3)
Title |
---|
JOST, W. H.: "Gastrointestinal motility problems in patients with Parkinson's disease: Effects of antiparkinsonian treatment and guidelines for management", DRUGS AND AGING, vol. 10, no. 4, 1997, pages 249 - 258 |
PFEIFFER, R. F.; QUIGLEY, E. M. M.: "Gastrointestinal motility problems in patients with Parkinson's disease: Epidemiology, pathophysiology, and guidelines for management", CNS-DRUGS, vol. 11, no. 6, 1999, pages 435 - 448 |
See also references of EP1778196A4 |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1827409A2 (en) * | 2004-11-24 | 2007-09-05 | Teva Pharmaceutical Industries Ltd. | Rasagiline orally disintegrating compositions |
EP1827409A4 (en) * | 2004-11-24 | 2008-03-19 | Teva Pharma | Rasagiline orally disintegrating compositions |
JP2008521808A (en) * | 2004-11-24 | 2008-06-26 | テバ ファーマシューティカル インダストリーズ リミティド | Rasagiline oral disintegrating composition |
US7598420B1 (en) | 2005-12-06 | 2009-10-06 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
US7619117B1 (en) | 2005-12-06 | 2009-11-17 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
AU2009204454B2 (en) * | 2008-01-11 | 2015-02-05 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations, their preparation and use |
JP2011509295A (en) * | 2008-01-11 | 2011-03-24 | テバ ファーマシューティカル インダストリーズ リミティド | Rasagiline formulation, its preparation and use |
WO2010026993A1 (en) | 2008-09-03 | 2010-03-11 | 武田薬品工業株式会社 | Method for improving absorbability of preparation, and preparation having improved absorbability |
WO2010070090A1 (en) * | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Solid composition containing the ingredient rasagiline |
EP2246321A1 (en) | 2009-01-23 | 2010-11-03 | Teva Pharmaceutical Industries Ltd | Delayed release rasagiline formulation |
DE202010017129U1 (en) | 2009-01-23 | 2011-09-14 | Teva Pharmaceutical Industries Ltd. | Rasagiline formulation with delayed release |
EP2218444A2 (en) | 2009-01-23 | 2010-08-18 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
US7855233B2 (en) | 2009-01-23 | 2010-12-21 | Teva Pharmaceutical Industries, Ltd. | Citrate salt of Rasagiline |
EP2308477A1 (en) | 2009-01-23 | 2011-04-13 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
US8080584B2 (en) | 2009-01-23 | 2011-12-20 | Teva Pharmaceuticals Industries, Ltd. | Delayed release rasagiline citrate formulation |
CN102341104A (en) * | 2009-03-05 | 2012-02-01 | 桑多斯股份公司 | Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)-, methanesulfonate |
US20120122993A1 (en) * | 2009-03-05 | 2012-05-17 | Sandoz Ag | Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-(1r)-, methanesulfonate |
WO2010100219A3 (en) * | 2009-03-05 | 2011-08-11 | Sandoz Ag | Pharmaceutical composition containing rasagiline mesylate |
WO2010111264A3 (en) * | 2009-03-24 | 2011-02-24 | Dr. Reddy's Laboratories Ltd. | Rasagiline formulations |
WO2010111264A2 (en) * | 2009-03-24 | 2010-09-30 | Dr. Reddy's Laboratories Ltd. | Rasagiline formulations |
EP2939669A1 (en) | 2009-12-22 | 2015-11-04 | Teva Pharmaceutical Industries, Ltd. | 3-keto-n-propargyl-1-aminoindan |
CN102791258A (en) * | 2010-02-03 | 2012-11-21 | 图必制药公司 | Extended release formulations of rasagiline and uses thereof |
RU2607595C2 (en) * | 2010-02-03 | 2017-01-10 | Фарма Ту Б Лтд. | Rasagiline compositions of prolonged release and use thereof |
WO2011095973A1 (en) * | 2010-02-03 | 2011-08-11 | Pharma Two B Ltd. | Extended release formulations of rasagiline and uses thereof |
RU2734632C2 (en) * | 2010-02-03 | 2020-10-21 | Фарма Ту Б Лтд. | Rasagiline compositions with prolonged release and use thereof |
EP3517103A1 (en) | 2010-02-03 | 2019-07-31 | Pharma Two B Ltd. | Extended release formulations of rasagiline and uses thereof |
US9943489B2 (en) | 2010-02-03 | 2018-04-17 | Pharmatwob Ltd. | Extended release formulations of rasagiline and uses thereof |
AU2011212068B2 (en) * | 2010-02-03 | 2016-08-18 | Pharma Two B Ltd. | Extended release formulations of rasagiline and uses thereof |
WO2011136373A1 (en) | 2010-04-30 | 2011-11-03 | 武田薬品工業株式会社 | Enteric tablet |
WO2011136376A1 (en) | 2010-04-30 | 2011-11-03 | 武田薬品工業株式会社 | Enteric tablet |
EP2600841A2 (en) * | 2010-05-30 | 2013-06-12 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of rasagiline |
WO2013105092A1 (en) * | 2012-01-12 | 2013-07-18 | Pharma Two B Ltd. | Fixed dose combination therapy of parkinson's disease |
US9504657B2 (en) | 2012-01-12 | 2016-11-29 | Pharmatwob Ltd. | Fixed dose combination therapy of Parkinson's disease |
EP2802319B1 (en) | 2012-01-12 | 2017-10-25 | Pharma Two B Ltd. | Fixed dose combination therapy of parkinson's disease |
CN104168896B (en) * | 2012-01-12 | 2018-08-10 | 图必制药公司 | The fixed dosage combination treatment of Parkinson's disease |
CN104168896A (en) * | 2012-01-12 | 2014-11-26 | 图必制药公司 | Fixed dose combination therapy of parkinson's disease |
EP2796130A3 (en) * | 2013-02-06 | 2015-02-25 | Galenicum Health S.L. | Immediate release tablets of rasagiline hemitartrate |
EP2764862A1 (en) * | 2013-02-06 | 2014-08-13 | Galenicum Health S.L. | Immediate release tablets of rasagiline hemitartrate |
Also Published As
Publication number | Publication date |
---|---|
JP2008507586A (en) | 2008-03-13 |
AU2005269416B2 (en) | 2011-07-28 |
US20060018957A1 (en) | 2006-01-26 |
EP1778196A2 (en) | 2007-05-02 |
WO2006014973A3 (en) | 2006-04-13 |
IL180706A0 (en) | 2007-06-03 |
EP1778196A4 (en) | 2008-12-17 |
CA2574925A1 (en) | 2006-02-09 |
AU2005269416A1 (en) | 2006-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005269416B2 (en) | Pharmaceutical dosage forms including rasagiline | |
JP5583597B2 (en) | Rasagiline formulation, its preparation and use | |
US7897173B2 (en) | Sustained-release, oral pharmaceutical formulations and methods of making and using same | |
EP1940361B1 (en) | Pharmaceutical dosage forms having immediate release and/or controlled release properties | |
EP1476138B1 (en) | Modified release formulations of at least one form of tramadol | |
US7094427B2 (en) | Combination immediate release controlled release levodopa/carbidopa dosage forms | |
US7611730B2 (en) | Tramadol-based medicament | |
CZ2002671A3 (en) | Medicinal formulation with retarded effect and containing tramadol saccharinate | |
JP5052602B2 (en) | Controlled dose drug delivery system | |
JP2008303223A (en) | Oral pulsed dose drug delivery system | |
EP1507518B1 (en) | Combination immediate release controlled release levodopa/carbidopa dosage forms | |
US20190105275A1 (en) | Oral pharmaceutical compositions of mesalazine | |
US20100040680A1 (en) | Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation | |
EP3445360B1 (en) | Oral pharmaceutical compositions of nicotinamide | |
US20080138411A1 (en) | Modified Release Formulations Of Selective Serotonin Re-Uptake Inhibitors | |
WO2023089553A1 (en) | Controlled release formulations of flavoxate and process for preparation thereof | |
KR20050016449A (en) | Combination immediate release controlled release levodopa/carbidopa dosage forms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 180706 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2574925 Country of ref document: CA Ref document number: 2005269416 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007523735 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005269416 Country of ref document: AU Date of ref document: 20050726 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005269416 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005782669 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005782669 Country of ref document: EP |